Genetics - TCD Undergraduate Open Day 2012
A talk from Genetics at the Undergraduate Open Day, December 2012, Trinity College Dublin. http://www.tcd.ieFrom:TRINITYCOLLEGEDUBLINViews:1 0ratingsTime:34:35More inEducation

Link:
Genetics - TCD Undergraduate Open Day 2012 - Video

Recommendation and review posted by Bethany Smith

Max Cooper feat BRAIDS - Pleasures [FIELDS]
Max Cooper has collaborated with Canada #39;s intellectual art-rockers BRAIDS on a two-part EP named CONDITIONS ONE. The first of a set of upcoming releases that examine the human condition, CONDITIONS ONE will be the first release on new electronica label FIELDS. The release is accompanied by evocative remixes by hotly tipped northern UK acts Ghosting Season and D/R/U/G/S, as well as an already-released free iPhone app Automaton that previewed one track of the EP, plus this beautiful hand-painted video by Cédric De Smedt. The human condition is a well-examined idea -- but as an ex-genetics researcher with a PhD, Cooper takes a somewhat aslant look at humanity with the two collaborations. "Pleasures," he says, "is just that -- an attempt to write something purely pleasurable and beautiful. But Automaton is darker -- an attempt to show how humans are essentially deterministic, trapped in a set of predictable reactions to their environment, their upbringing, their lives". All three members of BRAIDS sing, and the tracks on the CONDITIONS EP combine vocal lines, melodies and individual vocal sounds from every song on BRAIDS #39; most recent album, Native Speaker -- both as "proper vocals", and or ethereal, pure sound.From:Max CooperViews:361 6ratingsTime:04:12More inMusic

Follow this link:
Max Cooper feat BRAIDS - Pleasures [FIELDS] - Video

Recommendation and review posted by Bethany Smith

Sex Linked Traits and Pedigrees
Sex linked traits, pedigrees, geneticsFrom:Dan HoekstraViews:2 0ratingsTime:39:23More inEducation

More here:
Sex Linked Traits and Pedigrees - Video

Recommendation and review posted by Bethany Smith

XBOX GHOST (The HIdden)
#9658; #9658; #9658; Enjoy the video? Subscribe! bit.ly #9668; #9668; #9668; Download Here: http://www.hidden-source.com What is The Hidden? "In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation. This led to deeper research with dangerously unpredictable results, often leading to human patients losing their lives in irresponsible and immoral experiments. Time passed on, and by the mid 1990s the failure rate of the experiments had been reduced from 75% to a mere 15%, enough for Infinitum to move onto the next stage Biological Light Refraction. The British team were hoping to unravel the possibilities of light manipulation to create the perfect covert military agent. Early into the new millennium, due to a gross miscalculation, a series of tests on Subject 617 led to a massive synaptic trauma leaving the patient with multiple genetic anomalies. The subject was left in constant pain and with unstable DNA. The subject escaped captivity, killing anyone that got in its way. The IRIS (Infinitum Research Interception Squad) team have been deployed to return the subject to a maximum security Infinitum Research facility for further study and dissection. The entire project was considered a failure: all funding ceased and development was discontinued while all records and traces of the experiments ...From:SeaNannersViews:89123 6585ratingsTime:02:42More inGaming

Go here to see the original:
XBOX GHOST (The HIdden) - Video

Recommendation and review posted by Bethany Smith

Courtesy of Performance Genetics LLC, in collaboration with Equine Mechanics
Racehorse gallop at 500Hz, see those fetlocks buckle in an attempt to absorb the impact.From:Sian LawsonViews:0 0ratingsTime:00:13More inPeople Blogs

Read more:
Courtesy of Performance Genetics LLC, in collaboration with Equine Mechanics - Video

Recommendation and review posted by Bethany Smith

Prufenpuden Puppy In Development Personal Protection Dog For Sale
One of thirty five young pups we have in development at http://www.protectiondogsales.com It all starts with good genetics and the fact that we breed our own bloodlines going back seven generations of dogs we have owned, trained and titled sets up apart from all others. We know our dogs and we know how to develop these young dogs to their full potential and dogs that can be trusted with children, yet strong enough to challenge a man bent on harming your family. Check us out and watch them grow and develop into amazing personal protection family guardians. We sell everything from puppies with potential to fully trained, turn key, estate level protection dogs. Call for more detail. 502-542-9747 and ask for DavidFrom:harrisd1dogViews:4 0ratingsTime:00:35More inPets Animals

Read more:
Prufenpuden Puppy In Development Personal Protection Dog For Sale - Video

Recommendation and review posted by Bethany Smith

chocolate og kush #2
mgm geneticsFrom:growyourownmedicineViews:0 0ratingsTime:03:29More inNonprofits Activism

View original post here:
chocolate og kush #2 - Video

Recommendation and review posted by Bethany Smith

choclate og kush #1
mgm geneticsFrom:growyourownmedicineViews:3 0ratingsTime:04:10More inNonprofits Activism

See the rest here:
choclate og kush #1 - Video

Recommendation and review posted by Bethany Smith

AMES, Iowa, Dec. 13, 2012 /PRNewswire/ --NewLink Genetics Corporation (NLNK) today announced that the results of a Phase 1 dose escalation study with its proprietary HyperAcute Prostate Cancer Immunotherapy were published in the Journal of Immunotherapy. The article, entitled "Cellular Immunotherapy Study of Prostate Cancer Patients and Resulting IgG Responses to Peptide Epitopes Predicted From Prostate Tumor-associated Autoantigens," is featured in the current edition of the Journal.

The study was conducted at the University of Nebraska Medical Center and included eight patients. Patients were scheduled to receive a priming dose on day one, followed by eleven boost doses every two weeks and patients received up to 12 intradermal vaccinations at doses ranging from 30 million to 500 million cells per injection. Patients were tested for safety, immunological and clinical responses arising after immunotherapy.

The study demonstrated that the immunotherapy was safe, and that the first immunization differentially increased the anti-alphaGal IgG response in all patients compared with baseline levels. These data indicated that administration of HyperAcute-Prostate immunotherapy increases the immune response against alphaGal epitopes, demonstrating the immunogenicity of the vaccine in prostate cancer patients.

The patients that received the highest dose of immunotherapy developed antibody responses against prostate tumor-associated antigens that were not seen in a control group of untreated volunteers. Data demonstrated that 37.5 percent (3/8) of patients responded with Prostate Specific Antigen (PSA) level stabilization for more than 100 days.

The adverse events data reported in this publication confirm the safety of this immunotherapy, consistent with previous studies on the safety of alpha-Gal-expressing allogeneic vaccines (HyperAcute immunotherapy) in the treatment of lung, melanoma and pancreatic cancers. Median overall survival for the study was 25.1 months with one patient with bone metastases surviving for more than 70 months.

"The favorable safety profile of this agent combined with evidence of vaccine induced immunologic responses in patients clearly suggests this therapy should be studied in a large controlled trial," said Dr. George P. Hemstreet, III, University of Nebraska Medical Center, the Principal Investigator for the study.

NewLink Genetics is currently evaluating its lead immunotherapy product candidate algenpantucel-L (HyperAcute-Pancreas) in a Phase 3 clinical trial in surgically-resected pancreatic cancer patients.

About HyperAcute Prostate Cancer Immunotherapy

NewLink's HyperAcute Prostate Cancer immunotherapy product candidate consists of two allogeneic prostate cancer tumor cell lines modified to express alpha-Gal. These cell lines were chosen to provide a broad coverage of prostate cancer antigens. Each of the modified cell lines is grown in large cultures, harvested, packaged and irradiated. Each of the two vaccine components was administered separately.

About Prostate Cancer

More here:
Clinical Data from NewLink Genetics' HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy

Recommendation and review posted by Bethany Smith

Gene Therapy Second Period Mr. Bell
From:bellshonorsbioViews:0 0ratingsTime:02:24More inEducation

Read this article:
Gene Therapy Second Period Mr. Bell - Video

Recommendation and review posted by Bethany Smith

Bharat Book Presents: Single-Use Technologies for Biopharmaceuticals Global Markets
For more information kindly visit: http://www.bharatbook.com REPORT HIGHLIGHTS This report provides: An overview of biopharmaceutical single-use technologies, which aids the manufacturing process in overcoming such complex issues as sterilization and critical manufacturing parameters Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017 In-depth discussion of key market segments, such as membrane adsorbers, bioreactors, mixing, tangential flow filtration, tubing, connectors, preassembled tubing and rigging, depth filtration, buffer containers, waste containers, samplers, media bags, and filter cartridges Delineation of market application areas, such as monoclonal antibodies, vaccines, gene therapy, recombinant proteins, blood derivatives, and anticancer drugs Identification of supply chain participants, including contract manufacturing organizations, biopharma operating companies/manufacturing, and systems integrators, and their respective market shares Key restraints in the industry, including leachables and extractables, cost constraints, breakage of bags, and environmental concerns Comprehensive company profiles of existing and potential market players Patent analysis. REPORT SCOPE INTRODUCTION STUDY BACKGROUND Eliminating the risk of contamination is the greatest challenge faced by manufacturers of biopharmaceuticals, and currently this requires high level monitoring of critical ...From:Pharma3bViews:0 0ratingsTime:01:11More inScience Technology

Read more here:
Bharat Book Presents: Single-Use Technologies for Biopharmaceuticals Global Markets - Video

Recommendation and review posted by Bethany Smith

AXA y Ponle Freno, promoting road safety AXA Vdeo Oficial
Fun running race #39;Ponle Freno #39; 4th edition took place in Madrid on November 25. It was the first action since AXA entered into strategic partnership with Ponle Freno social platform. And because of that, we did our best to make it a resounding success. The outcome couldn #39;t be better: bull; Record number of participants, with a large number of AXA employees and their relatives running bull; Fundraising record. Money will support a research project on stem cell therapy for spinal cord injury at Puerta de Hierro Hospital (Madrid). bull; Launching of new app ( #39;Corremos Juntos #39;) that allowed thousands of people to participate in the race all over the world for the first time. bull; AXA employees showed their engagement and commitment to the project, with hundreds running in Madrid and also in some other cities in Spain thanks to the app. In short, an unforgettable day for all people worried about road safety, as shown in the video above. axa.es "Like Music" by Admiral Bob (feat. snowflake) ccmixter.org is licensed under a Creative Commons license: creativecommons.orgFrom:AXASEGUROSESViews:33 0ratingsTime:03:21More inNonprofits Activism

Here is the original post:
AXA y Ponle Freno, promoting road safety ® AXA Vídeo Oficial - Video

Recommendation and review posted by simmons

Nick #39;s Story
MedStar National Rehabilitation Hospital patient Nick Balenger suffered a spinal cord injury while vacationing in Hawaii. WJLA recaps Nick #39;s story and shows how far he has come since his injury.From:nrhrehabViews:0 0ratingsTime:03:26More inNonprofits Activism

Follow this link:
Nick's Story - Video

Recommendation and review posted by sam

Spinal Cord Injury Australia
Music by LovesonicFrom:martyn4933Views:0 0ratingsTime:01:02More inEntertainment

See the rest here:
Spinal Cord Injury Australia - Video

Recommendation and review posted by sam

SU2C-CRI Cancer Immunology Translational Research Dream Team
Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI) announce the formation of a Dream Team project dedicated to cancer immunology mdash; "Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy." Cancer immunology is a field of research that explores the complex relationship between cancer and the immune system, with the goal of discovering immune-based solutions to curing cancer. The SU2C-CRI Cancer Immunology Translational Research Dream Team will receive $10 million in funding over three years for this translational cancer research project that will unite laboratory and clinical efforts leading to the immunological treatment, control and prevention of cancer. The team will be led by James P. Allison, Ph.D., and Antoni Ribas, MD, Ph.D. Allison is chairman of the department of immunology, director of the immunotherapy platform and co-director of the David H. Koch Center for Applied Research of Genitourinary Cancers at The University of Texas MD Anderson Cancer Center. Ribas is professor of medicine, surgery and molecular and medical pharmacology, director of the tumor immunology program area at the Jonsson Comprehensive Cancer Center, and member of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles (UCLA). "The goal of our Dream Team is to expand, optimize and explore combinations of two novel immunotherapies, immune checkpoint blockade and adoptive T-cell transfer ...From:CancerResearchInstViews:14 2ratingsTime:03:37More inNonprofits Activism

See the article here:
SU2C-CRI Cancer Immunology Translational Research Dream Team - Video

Recommendation and review posted by sam

Passfail.com News: Harvard Bioscience Announces Filing of IPO Registration Stat...
Harvard Bioscience (HBIO), a global developer, manufacturer and marketer of a broad range of tools to advance life science research and regenerative medicine, announced that its wholly-owned subsidiary, Harvard Apparatus Regenerative Technology, Inc., filed a registration statement with the SEC for an initial public offering, or IPO, of Harvard Apparatus Regenerative Technology #39;s common stock. Following the IPO, Harvard Apparatus Regenerative Technology will own Harvard Bioscience #39;s regenerative medicine device business, which develops life-saving medical devices in the field of regenerative medicine, including devices to be used by physicians for growing organs outside the body for transplant. Following the IPO, Harvard Bioscience will own at least 80% of Harvard Apparatus Regenerative Technology #39;s common stock. Harvard Bioscience intends to distribute its remaining interest in Harvard Apparatus Regenerative Technology to Harvard Bioscience #39;s shareholders in a pro-rata, tax-free dividend approximately 120 days following the closing of the IPO. Summer Street Research Partners will act as sole book-running manager for the offering. This is Sayoko Murase for Passfail.com, taking you behind the ticker. For Passfail.com, Behind The Ticker (TM) Pass Fail NewsFrom:passfailtvViews:0 0ratingsTime:01:15More inNews Politics

Visit link:
Passfail.com News: Harvard Bioscience Announces Filing of IPO Registration Stat... - Video

Recommendation and review posted by sam

BioLife Solutions Inc: Ticker Symbol BLFS
investorials.com BioLife Solutions Inc., ticker symbol BLFS, is a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, as well as a contract aseptic media manufacturer. The company #39;s three product lines help regenerative medicine, drug discovery and bio-banking companies reduce cell damage and death during transportation and while in storage. The company also owns and operates a contract manufacturing business that has generated significant revenues and helped reduced its own manufacturing costs. To learn more about BioLife Solutions, visit their Investorial at www dot Investorials dot com slash companies slash BLFS.From:InvestorialsViews:0 0ratingsTime:00:55More inEducation

Follow this link:
BioLife Solutions Inc: Ticker Symbol BLFS - Video

Recommendation and review posted by sam

Stem Cell Therapy and Medical Tourism: Of Promise and Peril?
From:harvardstemcellViews:9 0ratingsTime:01:15:50More inScience Technology

Read more:
Stem Cell Therapy and Medical Tourism: Of Promise and Peril? - Video

Recommendation and review posted by Bethany Smith

Avascular necrosis stem cell therapy in mumbai
This video explores the patient #39;s condition before and after treatment.It is published by StemRx India. Avascular necrosis stem cell therapy in mumbai for more information visit http://www.stemrx.inFrom:StemRx BioScienceViews:3 0ratingsTime:04:07More inScience Technology

Read more:
Avascular necrosis stem cell therapy in mumbai - Video

Recommendation and review posted by Bethany Smith

"Cell therapy is now being used for carpal tunnel syndrome at the Center for Regenerative Medicine." According to Dr. Farshchian.

(PRWEB) December 11, 2012

"Current studies seem to be very impressive with use of regenerative medicine in orthopedic problems," A.J. Farshchian MD From the Center for Regenerative Medicine said earlier in a discussion on arthritis and sports injuries.

Sports injuries need an adequate blood supply and cellular migration. Platelet-derived growth factors are critically involved in this process. These cells allow the body to take advantage of the normal healing pathways at a greatly accelerated rate. During the healing process, the body rushes many cells and cell-types to the injected area in order to accelerate the healing process. These cells perform many functions, including release of growth factors (GF) into the diseased or arthritic and injured sites.

Carpal tunnel syndrome occurs when the median nerve, which runs from the forearm into the hand, becomes pressed or squeezed at the wrist. The median nerve controls sensations to the palm side of the thumb and fingers except for the fifth digit or also known as little finger. The median nerve also carries impulses to some small muscles in the hand that allow the fingers to move. The carpal tunnel is a narrow, rigid passageway of ligament and bones at the base of the hand which contains the median nerve.

Sports injuries need an adequate blood supply and cellular migration. Platelet-derived growth factors are critically involved in this process. These cells allow the body to take advantage of the normal healing pathways at a greatly accelerated rate. During the healing process, the body rushes many cells and cell-types to the injected area in order to accelerate the healing process. These cells perform many functions, including release of growth factors (GF) into the diseased or arthritic and injured sites.

Sometimes thickening from irritated tendons or other swelling narrows the tunnel and causes the median nerve to be compressed. The result may be pain, weakness, or numbness in the hand and wrist, radiating up the arm. Although painful sensations may indicate other conditions, carpal tunnel syndrome is the most common and widely known of the entrapment neuropathies in which the body's peripheral nerves are compressed or traumatized. Symptoms of carpal tunnel syndrome starts gradually, with frequent burning, tingling, or itching numbness in the palm of the hand and the fingers, especially the thumb and the index and middle fingers. Some carpal tunnel sufferers say their fingers feel useless and swollen, even though little or no swelling is apparent.

The symptoms often first appear in one or both hands during the night, since many people sleep with flexed wrists. A very common symptom is the patient may wake up from sleep, feeling the need to "shake out" the hand or wrist. As symptoms worsen, people might feel tingling during the day. Decreased grip strength may make it difficult to form a fist, grasp small objects, or perform other manual tasks. In chronic and/or untreated cases, the muscles at the base of the thumb may waste away. Some people are unable to tell between hot and cold by touch.

Carpal tunnel syndrome is often the result of a combination of factors that increase pressure on the median nerve and tendons in the carpal tunnel, rather than a problem with the nerve itself. There may be a genetic factor since the carpal tunnel is simply smaller in some people than in others. Other contributing factors include trauma or injury to the wrist that cause swelling, such as sprain or fracture, mechanical problems in the wrist joint, fluid retention during pregnancy or menopause, work stress, repeated use of vibrating hand tools rare causes such as over activity of the pituitary gland; hypothyroidism; rheumatoid arthritis; or the development of a cyst or tumor in the canal are possible as well. There is little clinical data to prove whether repetitive and forceful movements of the hand and wrist during work or leisure activities can cause carpal tunnel syndrome.

Repeated motions performed in the course of normal work or other daily activities can result in repetitive motion disorders such as bursitis and tendonitis. Women are three times more likely than men to develop carpal tunnel syndrome, perhaps because the carpal tunnel itself may be smaller in women than in men. The dominant hand is usually affected first and produces the most severe pain. Persons with diabetes or other metabolic disorders that directly affect the body's nerves and make them more susceptible to compression are also at high risk. Carpal tunnel syndrome usually occurs only in adults.

Continued here:
Dr. Farshchian: Cell Therapy is Now Being Used for Carpal Tunnel Syndrome at the Center for Regenerative Medicine

Recommendation and review posted by Bethany Smith

Proof-of-concept animal study selected as one of the best presentations at 54thAmerican Society of Hematology Annual Meeting and Exposition

BOSTON, Dec. 11, 2012 /PRNewswire-USNewswire/ -- Researchers at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) have taken the first preliminary steps toward developing a form of gene therapy for sickle cell disease. In an abstract presented on Dec. 10 at the 54th annual meeting of the American Society of Hematology, the research teamled by DF/CHCC's Raffaele Renella, MD, PhD, Stuart H. Orkin, MD, and David A. Williams, MDannounced that they had demonstrated in an animal model the feasibility of activating a form of hemoglobin unaffected by the sickle cell mutation.

The study was included as part of the meeting's Best of ASH session on Dec. 11. At this session, the meeting's scientific co-chairs present what they consider to be the best abstracts of the 4,000-plus presented at the conference.

"This work builds on the transformative basic research discovery of the role of BCL11A in maintaining fetal hemoglobin silencing by the Orkin laboratory with a near-term goal of curing sickle cell disease using gene therapy," said Williams, chief of the Division of Hematology/Oncology at DF/CHCC and senior author on the abstract. "We have had important recent successes in applying this type of gene therapy in treating several other genetic diseases at Boston Children's Hospital."

The team's work builds on previous research, published by Orkin's laboratory, suggesting that strategies targeting a molecular switch called BCL11A have the potential to correct sickle cell disease.

First described over 100 years ago, sickle cell disease (or sickle cell anemia) is an inherited blood disease caused by a single mutation in one of the components of hemoglobin, the oxygen-carrying protein in red blood cells. The mutation reduces the protein's ability to carry oxygen and forces the cells to curve into a distinctive crescent or sickle shape.

Our bodies can actually manufacture two forms of hemoglobin: the adult form susceptible to the sickle cell mutation, and a fetal form that is largely produced during development and for a short time after birth. BCL11A is a transcription factor that facilitates that shift in hemoglobin production. Fetal hemoglobin expression significantly reduces the symptoms and complications of sickle cell disease because it prevents the intracellular abnormalities caused by the sickle mutation.

In their abstract, Renella, Orkin, Williams and their colleagues reported on their efforts to develop a combined lentiviral gene transfer/RNA interference approach capable of turning down BCL11A in vitro in human and mouse cells and in vivo in a mouse bone-marrow transplant model. Among their findings, the researchers documented a five- to 20-fold increase in fetal hemoglobin production in treated mice.

The team is quick to note that they have not yet attempted to correct disease in a model of sickle cell using this approach. Such efforts would be carried out in future studies.

"There are many approaches to sickle cell disease, and while we've shown we can develop viral vectors, knock down BCL11A, and induce fetal hemoglobin production, it's all been done in non-disease model systems," cautioned Renella, a fellow in the Williams laboratory at DF/CHCC. "What we don't yet know is whether we can stop production of sickled cells in a sickle cell system. Further experiments will show us if that is possible."

See original here:
Potential gene therapy approach to sickle cell disease highlighted at ASH

Recommendation and review posted by Bethany Smith

Washington, December 12 (ANI): In a new study, researchers have shed more light on how an anti-aging gene suppresses cancer growth.

According to the new joint study by the University of Michigan Health System and Harvard Medical School, loss of the SIRT6 protein in mice increases the number, size and aggressiveness of tumors.

The study also suggests that the loss of SIRT6 promotes tumor growth in human colon and pancreatic cancers.

"It is critical to understand the spectrum of genes that suppress tumor development," co-senior author David Lombard from U-M Medical School said.

"Our research suggests SIRT6 may have a critical role in blocking cancer and controlling cellular metabolism. We hope to build on this work to better understand how this protein suppresses tumor development, and provide insight into potential future means of reprogramming cancer metabolism," he said.

The research was done in conjunction with the Massachusetts General Hospital Cancer Center at Harvard Medical School. Raul Mostoslavsky, M.D., Ph.D., assistant professor of medicine at Harvard Medical School, was the co-senior author.

The new research highlights the role SIRT6 plays in dampening cancer growth by repressing aerobic glycolysis - a major feature of cancer cells that involves the conversion of glucose to lactate. SIRT6 also inhibits activity of the key cancer gene Myc.

Many studies in cancer biology have focused on the importance of tumor suppressor proteins and how they may protect cells from progressing to cancer.

The new research follows up on previous studies that have tied SIRT6 to longevity in male mice. Other research has also shown that the protein may protect against diet-induced obesity.

"This work points to the conservation of biological mechanisms between lower organisms and humans, and the importance of fundamental basic research," Lombard said.

Read more:
Anti-aging gene 'may help suppress tumours'

Recommendation and review posted by Bethany Smith

The search for a "gay gene" may be off-target, new research finds. Another process called epigenetics that switches genes on and off may explain why homosexuality runs in families.

Epigenetics are heritable changes caused by factors other than DNA. Instead of traits getting passed down through the genes, epigenetic change happens because of the way genes are regulated, or turned on and off.

These genetic regulators may be the reason homosexuality persists in nature despite the fact that gay people are less likely to reproduce, suggests the new study published in the journal The Quarterly Review of Biology.

"These things have evolved because they're good for the parents, but they sometimes, not [with] high frequency, but sometimes carry over" into offspring, study researcher William Rice, an evolutionary geneticist at the University of California, Santa Barbara, told LiveScience. In a male fetus, Rice and his colleagues write, an epigenetic change that benefited the mother may lead to "feminization" of sexual preference homo- or bisexuality. The same may be true for epigenetic changes passed down by dad to a female fetus. (The terms feminization and masculinization of sexual preference refer to sexual orientation only not to physical or personality traits of the offspring.)

The findings add to past research suggesting gay men haven't died out, because female relatives of gay men tend to have more children on average than other females. The study researchers specifically found that two genes passed on through the maternal line could produce this effect.

Hormones, epigenetics and orientation

Rice and his colleagues focused on epi-marks, which are molecular changes that act like temporary "switches" to turn genes on and off. If a gene is a blueprint, the epi-mark is the construction foreman who makes sure the product gets built. An epi-mark also determines when, where and how much a gene is expressed, according to the National Institute for Mathematical and Biological Synthesis.

These molecular switches are usually erased very early in the developmental process, but they can be passed down from generation to generation, too, Rice said.

Some epi-marks are particularly important during fetal development, when they promote normal physical development in the sexes despite natural variations in testosterone during pregnancy. Researchers know that fetal exposure to too much testosterone can masculinize the genitals, brain or behavior of a genetically female fetus. Likewise, too little testosterone can make a genetically male fetus more feminized. [Image Gallery: Fetal Development in Womb]

But here's the catch: There's lots of overlap between the levels of testosterone male and female fetuses get exposed to. That means there must be another side to the story, Rice and his colleagues wrote.

Read this article:
Gene Regulation May Explain How Homosexuality Flourishes

Recommendation and review posted by Bethany Smith

Gene X (2012) full movie.avi
This short movie has been made by a group of M. Sc Biotechnology students, as part of our "creativity assignment" for the Genetic Engineering subject. The work is purely fiction, and made only for entertainment. Do not try to find any scientific logic in the movie, just sit back, relax, watch, and enjoy!! Thanks!! - M. Sc Biotechnology (2011-13) VIT University, India PS- Feel free to comment your views on our humble effort..From:Subham BasuViews:0 0ratingsTime:27:29More inEducation

Here is the original post:
Gene X (2012) full movie.avi - Video

Recommendation and review posted by Bethany Smith

DoYoung,DongKon,Steven Genetic.mov
This is a short video showing the basic of genetic engineering in Science class. Made by 9.2, Steven, DongKon and DoYoung. Enjoy~From:Steven NgViews:0 0ratingsTime:01:57More inEntertainment

Read the original:
DoYoung,DongKon,Steven Genetic.mov - Video

Recommendation and review posted by Bethany Smith